Our recent work analyzing multi-region organoids reveal inter- and intra-tumor pharmacogenomic heterogeneity in primary liver cancer, in collaberation with Prof. Zhang Ning. Please read the article published in Cancer Cell for more details.
We present NUWA, a computational pipeline for robust inference of protein abundances missing in mass spectrometry proteomic profiles. …
Inter- and intra-tumor heterogeneity is a major hurdle in primary liver cancer (PLC) precision therapy. In collaboration with Prof. …
β-Arrestin 1 (ARRB1) has been known as a key negative regulator of G protein-coupled receptor signaling. During the past decade, it has …
We provide the Reproducible Prognosis Molecular Signature platform (ReProMSig), to facilitate biomarker development and applications in …
By integrative analysis of label-free proteomes of Matrigel and SILAC proteomes of organoids collected by three methods respectively, …
Combining whole exome sequencing, RNA-sequencing, and mass spectrometry-based proteomic profiling to elucidate GC molecular landscape.
ICGC-ARGO Project: Genomic and Proteomic Characterisation of Gastric Cancer.
An integrated platform for protein interaction network construction, filtering, analysis, visualization and cancer-context annotation.
A powerful Cancer Virtual Cohort Discovery Analysis Platform with large cancer datasets integrated.
Our recent work analyzing multi-region organoids reveal inter- and intra-tumor pharmacogenomic heterogeneity in primary liver cancer, in collaberation with Prof. Zhang Ning. Please read the article published in Cancer Cell for more details.
ReProMSig (Reproducible Prognosis Molecular Signature) has been online at Briefings in Bioinformatics. Congratulations to Tingting Zhao and Lihua Cao!
We are excited to be a part of a Lancet Oncology Commission focusing on cancer genomics and precision oncology. This new commission will be coordinated by the International Cancer Genome Consortium Accelerating Research in Genomic Oncology (ICGC-ARGO) initiative, and bring together international experts with relevant expertise across a range of fields, to offer practical solutions for key challenges in ensuring sustainable and equitable access to omics testing and a blueprint for advancing cancer diagnosis and treatment.
Open positions for research faculty and students